diabetes type2 Archives - CRS. Experts. Early Phase.

Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.

Science 10. November 2022

First published in Diabetes Technology & Therapeutics on 2010 Aug.Diabetes Technol Ther. 2010 Aug;12(8):599-604. doi: 10.1089/dia.2010.0019 Authors: Pfützner A, Derwahl...

Read Article

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin.

Science 28. September 2022

ShareTwitter FacebookXingLinkedin

This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.

Read Article

Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients.

Science 26. September 2022

ShareTwitter FacebookXingLinkedin

This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.

Read Article

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Science 20. April 2020

ShareTwitter FacebookXingLinkedin

Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. I

Read Article